Biofrontera AG (BFRA): Price and Financial Metrics


Biofrontera AG (BFRA): $5.47

0.12 (+2.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BFRA POWR Grades


  • BFRA scores best on the Value dimension, with a Value rank ahead of 85.47% of US stocks.
  • The strongest trend for BFRA is in Momentum, which has been heading down over the past 173 days.
  • BFRA's current lowest rank is in the Quality metric (where it is better than 18.06% of US stocks).

BFRA Stock Summary

  • BFRA's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 550.43 -- higher than 94.46% of US-listed equities with positive expected earnings growth.
  • With a year-over-year growth in debt of 924.7%, Biofrontera AG's debt growth rate surpasses 98.42% of about US stocks.
  • Revenue growth over the past 12 months for Biofrontera AG comes in at 375.12%, a number that bests 97.76% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to BFRA, based on their financial statements, market capitalization, and price volatility, are CETX, MGIC, OPK, VOXX, and TBLT.
  • Visit BFRA's SEC page to see the company's official filings. To visit the company's web site, go to www.biofrontera.com.

BFRA Stock Price Chart Interactive Chart >

Price chart for BFRA

BFRA Price/Volume Stats

Current price $5.47 52-week high $9.87
Prev. close $5.35 52-week low $4.67
Day low $5.33 Volume 1,400
Day high $5.50 Avg. volume 53,498
50-day MA $5.88 Dividend yield N/A
200-day MA $6.44 Market Cap 155.12M

Biofrontera AG (BFRA) Company Bio


Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatologically tested cosmetics for the treatment and care of diseased skin. Biofrontera AG was founded in 1997 and is based in Leverkusen, Germany.


BFRA Latest News Stream


Event/Time News Detail
Loading, please wait...

BFRA Latest Social Stream


Loading social stream, please wait...

View Full BFRA Social Stream

Latest BFRA News From Around the Web

Below are the latest news stories about Biofrontera AG that investors may wish to consider to help them evaluate BFRA as an investment opportunity.

Photodynamic Therapy Global Market Report 2021: COVID-19 Implications And Growth

Major players in the photodynamic therapy market are Theralase Technologies Inc. , Biofrontera AG, Hologic Inc. , Bausch Health, Quest PharmaTech Inc. , LUMIBIRD, Galderma Laboratories L. P. , Sun Pharmaceutical Industries Limited, Allergan plc, Modulight Inc. Major players in the photodynamic therapy market are Theralase Technologies Inc. , Biofrontera AG, Hologic Inc. , Bausch Health, Quest PharmaTech Inc. , LUMIBIRD, Galderma Laboratories L. P. , Sun Pharmaceutical Industries Limited, Allergan plc, Modulight Inc.

Intrado Digital Media | September 9, 2021

Biofrontera reports preliminary revenue for the month of August 2021

Leverkusen, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the Company), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of August 2021.

Intrado Digital Media | September 8, 2021

Europe Dermatology Treatment Devices Market Growth and Trends to 2021-2027 With Top Companies Like Cutera Inc. Bausch Health Companies Inc. BIOFRONTERA AG Avita Medical Sciton, Inc. Lumenis Alma Lasers

The Europe dermatology treatment devices market is expected to reach US$ 2,198.26million in 2027 from US$ 1,380.20million in 2019. The market is estimated to grow with a CAGR of 6.2% from 2020-2027. The Business Market Insights provides you regional research analysis

OpenPR | August 19, 2021

Biofrontera reports financial results for the six months ended June 30, 2021

Leverkusen, Germany, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the Company), an international biopharmaceutical company, today reported its financial results for the six months ended June 30, 2021.

Intrado Digital Media | August 19, 2021

Chronic Urticaria Or Hives Drug Market to Show Incredible Growth by 2027 Covid-19 Analysis | ELORAC Inc., Biofrontera AG

This thorough Chronic Urticaria Or Hives Drug market research is a thorough evaluation of the restrains present in the market and planning properly based on this report to enhance your business. This report is a result of many aspects that

OpenPR | August 18, 2021

Read More 'BFRA' Stories Here

BFRA Price Returns

1-mo -3.36%
3-mo -16.81%
6-mo 14.44%
1-year -32.47%
3-year -60.77%
5-year N/A
YTD -24.97%
2020 N/A
2019 0.00%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7888 seconds.